Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||lung non-small cell carcinoma||not applicable||ADXS-503||Phase I||Actionable||In a Phase I trial, ADXS-503 monotherapy demonstrated manageable toxicity, resulted in stable disease as best response in 3 of 7 patients with metastatic non-small cell lung cancer (J Clin Oncol 38: 2020 (suppl; abstr e21682); NCT03847519).||detail...|
|PubMed Id||Reference Title||Details|
|A phase I study of ADXS-503 alone and in combination with pembrolizumab in subjects with metastatic squamous or non-squamous non-small cell lung cancer (NSCLC).||Full reference...|